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Abstract 
Background: Patients with type 2 diabetes mellitus (T2DM) are at high risk of cardiovascular mortality, but the mech-
anisms behind this remain unclear. Prothrombotic fibrin clot properties have been shown in T2DM and cardiovascular 
disease. We hypothesized that formation of denser clots, which are resistant to fibrinolysis, has a negative impact on 
cardiovascular mortality in T2DM.
Methods: We studied 133 T2DM patients aged 43–83 years. Plasma fibrin clot turbidity, permeation, compaction, 
and efficiency of clot lysis using 3 assays including the determination of maximum concentration (D-Dmax) and rate 
of increase in D-dimer concentration (D-Drate) released during tissue plasminogen activator-induced degradation, 
were evaluated at the time of enrollment, along with thrombin generation and fibrinolytic proteins. During a median 
follow-up period of 72 months, cardiovascular mortality was recorded.
Results: Cardiovascular deaths (n = 16, 12%) occurred more frequently in patients with increased D-Dmax 
(> 4.26 mg/l, hazard ratio [HR] 5.43, 95% confidence interval [CI] 1.99–14.79), or decreased D-Drate (< 0.07 mg/l/min, HR 
2.97, 95% CI 1.07–8.23), or increased peak thrombin (> 283.5 nM, HR 5.65, 95% CI 2.07–15.51). These predictors had an 
even more potent impact on cardiovascular mortality in patients with prior cardiovascular disease (64.7%) and with 
corresponding risks as follows: HR 6.18, 95% CI 2.02–18.96; HR 8.98, 95% CI 2.99–26.96; and HR 5.35, 95% CI 1.62–17.72, 
respectively. Other investigated fibrin variables and fibrinolytic proteins did not associate with cardiovascular mortal-
ity. In multivariable analysis, cardiovascular mortality was predicted by D-Dmax > 4.26 mg/l, age > 65 years, prior cardio-
vascular disease, and C-reactive protein > 3 mg/l.
Conclusions: This study is the first to show that formation of denser fibrin clots resistant to fibrinolysis could be a risk 
factor for long-term cardiovascular mortality in T2DM.
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Background
Type 2 diabetes mellitus (T2DM) is considered to be 
an epidemic of the twenty-first century, having a global 
prevalence of 9.3% in 2019 [1]. Over the last 15 years, 
the mortality and incidence of cardiovascular events 
has declined both in patients with and without T2DM, 
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Cardiovascular disease affects 32.2% of T2DM patients 
and leads to mortality in 9.9% of patients having T2DM 
of more than 10 years duration [3]. Coronary artery dis-
ease (CAD) and stroke are major contributors to overall 
mortality in T2DM patients [3, 4].
There is growing evidence which shows that pro-
thrombotic fibrin clot properties, including formation 
of more compact clots which are more resistant to lysis, 
are involved in atherothrombotic events such as myo-
cardial infarction and ischemic stroke [5–7]. Several 
groups have also shown an association of T2DM with a 
prothrombotic clot phenotype [8–12]. Of note, T2DM 
has been reported to unfavorably affect plasma fibrin 
clot characteristics, such as leading to hypolysability, 
in patients with concomitant advanced CAD [13, 14]. 
The mechanisms behind impaired clot susceptibility to 
lysis observed in T2DM are complex. It has been sug-
gested that hypofibrinolysis in T2DM is associated 
with elevated levels of plasminogen activator inhibi-
tor-1 (PAI-1) [15] and thrombin-activatable fibrinolysis 
inhibitor (TAFI) [16], along with increased cross-link-
ing of α2-antiplasmin into fibrin networks [8, 17], and 
glycation of fibrinogen [18] and plasminogen [19], 
while the mechanical properties of fibrin are independ-
ent from fibrinogen glycation [20]. Prolonged T2DM 
duration might also contribute to prothrombotic fibrin 
clot alterations including impaired fibrinolysis [12], 
with enhanced oxidative stress playing a substantial 
role [21]. Patient sex is also an important modulator of 
fibrin clot properties, both in T2DM and CAD patients 
[14, 22]. Asymptomatic women with coronary plaques, 
as visualized by coronary computed tomography angi-
ography, have reduced fibrin clot lysability compared 
to men with and without coronary plaques, and women 
without coronary plaques, suggesting a sex-dependent 
link between coronary atherosclerosis and fibrin clot 
lysability [22].
Fibrinogen, the main component of fibrin, has been 
reported to be predictive of major adverse cardiovascular 
events, especially among diabetic patients, both follow-
ing acute coronary syndrome [23] and in those with sta-
ble coronary disease [24]. Moreover, fibrin clots that are 
resistant to lysis have predicted adverse outcome in dia-
betic patients following acute coronary syndrome [25]. 
The same was true for maximum turbidity. In another 
study [26], area under the turbidity curve, but not the 
turbidity lysis time, associated with cardiovascular events 
in CAD patients, also after adjustment for T2DM, which 
was diagnosed in 29% of the study participants. To the 
best of our knowledge, there have not been any published 
reports investigating the long-term impact of fibrin clot 
phenotype on mortality in T2DM patients. We hypoth-
esized that formation of denser clots, which are more 
resistant to fibrinolysis, leads to increased long-term car-
diovascular mortality in T2DM.
Methods
Patients
Patients were recruited from March 2011 to November 
2011 from the John Paul II Hospital, Krakow, Poland. The 
study population was previously described in detail [12]. 
Briefly, 156 patients with T2DM aged 18 years or greater 
who fulfilled the American Diabetes criteria for diagno-
sis of T2DM were enrolled. Patients were excluded if they 
presented with signs of acute infection, suffered from 
arterial or venous thromboembolic events within the 
six months prior to enrollment, were treated with anti-
coagulants at the time of enrollment, or were diagnosed 
with cancer, chronic inflammatory disease, liver injury, 
or stage 4 or 5 chronic kidney disease. Pregnant women 
were also excluded.
Data collected in the questionnaire included demo-
graphic data, time since T2DM diagnosis, comorbidities, 
and medications used. Obesity was defined as body-mass 
index > 30  kg/m2. Hypercholesterolemia was defined as 
low-density lipoprotein (LDL) cholesterol > 2.5  mmol/l 
or ongoing lipid-lowering treatment [27]. Other comor-
bidities were defined as previously described [12]. The 
study was approved by the local bioethics committee. All 
patients provided informed written consent.
Laboratory investigations
At baseline, fasting blood samples were obtained from 
the antecubital vein between 8:00 and 10:00 am. Gly-
cated hemoglobin (HbA1c), fasting glucose, creatinine, 
lipid profile, and high sensitivity C-reactive protein 
(CRP) were assayed by routine laboratory techniques. 
Fibrinogen was determined with the von Clauss method. 
Plasminogen and α2-antiplasmin were measured using 
chromogenic assays (STA Stachrom α2-antiplasmin and 
plasminogen, Diagnostica Stago, Asnieres, France). Com-
mercially available immunoenzymatic assays were used 
to measure tissue plasminogen activator (tPA) antigen 
(TintElize, Umea, Sweden), PAI-1 antigen (American 
Diagnostica, Stamford, CT, USA), TAFI antigen (Chro-
mogenix, Lexington, MA, USA), and soluble thrombo-
modulin (Diagnostica Stago).
Plasma thrombogenic potential was assessed using 
calibrated automated thrombography (Thrombinoscope 
BV, Maastricht, the Netherlands) in a 96-well plate fluo-
rometer (Ascent Reader, Thermolab systems OY, Hel-
sinki, Finland) at 37  °C according to the manufacturer’s 
instructions. A volume of 80  µl of platelet-poor plasma 
was diluted with 20  µl of a commercially available tis-
sue factor-based activator (Diagnostica Stago) con-
taining 5  pmol/l recombinant tissue factor, 4  µmol/l 
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phosphatidylserine/phosphatidylcholine/phosphatidyle-
thanolamine vesicles, and 20 µl of FluCa solution (Hepes, 
pH 7.35, 100  nmol/l  CaCl2, 60  mg/ml bovine albumin, 
and 2.5  mmol/l Z-Gly-Gly-Arg-amidometylcoumarin). 
The peak thrombin level was analysed [28]. Plasma sam-
ples were analyzed in duplicate, and the intra-assay vari-
ability was 6%.
Fibrin clot parameters, assayed at the time of enroll-
ment, included: turbidity, permeation, compaction, lysa-
bility, maximum concentration (D-Dmax), and rate of 
D-dimer (D-Drate) released during tPA-induced clot lysis, 
and were previously described in detail [12]. Two param-
eters were assayed during turbidity measurements: lag 
phase, which reflects the time required for fibrin protofi-
brils to grow to a sufficient length to allow for lateral 
aggregation, and maximum absorbance at plateau 
(ΔAbs), which reflects fiber cross-sectional area. Plasma 
was diluted 2:3 with 0.05 mol/l Tris buffer and was incu-
bated with 1 U/ml human thrombin (Sigma) and 
16 mmol/l calcium chloride. Absorbency was read every 
7  s at 350  nm for 15  min with a Dynex MRX2 plate 
reader. Lag phase was recorded as the time needed for 
absorbency to change by 0.01 from baseline [29]. Fibrin 
clot permeation was determined by measuring flow rates 
of buffer through the fibrin clots obtained from the 120 µl 
of citrated plasma, by adding 20 mmol/l calcium chloride 
and 1 U/ml human thrombin, as previously described 
[30, 31]. The mass of consecutive drops through each 
tube during a period of 60  min was recorded for exact 
volume. A permeation coefficient  (Ks), indicating the 
average size of fibrin clot pores, was calculated from the 
following equation:  Ks = 
Q×L×η
t×A×p
 , where Q is the flow rate 
in time (t); L is the length of a fibrin gel; η is the viscosity 
of liquid (in poise); A is the cross-sectional area (in 
square centimeters), and Δp is the differential pressure 
(in dynes per square centimeter). To assess compaction, 
the citrated plasma was mixed (3:2) with 0.7  IU/ml 
thrombin, 0.1% Tween 80, and 20 mmol/l calcium chlo-
ride in TBS, and then clots were formed in tubes pre-
pared as in the permeation experiments [31, 32]. After 
centrifugation at 6000 g for 60 s, the volume of superna-
tant evacuated from the tubes was assessed based on the 
difference in mass of the tube. Compaction was expressed 
as this volume divided by the initial plasma volume used 
to form the fibrin clot. Two plasma clot lysis assays were 
performed. In the modified assay by Lisman et  al. [33], 
citrated plasma was mixed (1:1) with HEPES buffer con-
taining calcium chloride (final concentration, 17 mmol/l), 
diluted recombinant tissue factor (final dilution  105 
times; Innovin, Dade Behring), phospholipid vesicles 
(final concentration, 10  µmol/l), and recombinant tPA 
(rtPA, final concentration, 30 U/mL, 56  ng/mL; 
Boehringer Ingelheim, Ingelheim, Germany). Clot lysis 
time (CLT) was defined as time from the midpoint of the 
baseline to maximum turbid transition, to the final pla-
teau phase. In the second assay, using the modified 
approach by Williams et  al. [34], 1  µg/ml rtPA 
(Boehringer Ingelheim) was added simultaneously with 
human thrombin. This lysis time was defined as the time 
required for a 50% decrease in clot turbidity measured at 
405  nm  (t50%) at 37  °C in a Spectra Max 340 kinetic 
microplate reader (Molecular Devices, Sunnyvale, CA, 
USA). Finally, plasma lysis was assessed using a modified 
version of the method described by Collet et al. [35, 36]. 
The plasma samples were recalcified with calcium chlo-
ride (final concentration, 20  mmol/l) and then 1  U/ml 
human thrombin (Sigma-Aldrich, St Louis, MO, USA) 
was added. After 2 h of incubation at room temperature, 
tubes containing the clots were connected via plastic tub-
ing to a reservoir with buffer (0.05 M Tris–HCl, 0.15 M 
NaCl, pH 7.5), containing 0.2 µM rtPA. The lysis rate was 
determined by measuring the concentration of released 
D-dimers (American Diagnostica), a marker of plasmin-
mediated fibrin degradation, in the eluate every 20 min. 
Two measures of fibrin clot architecture, namely the high 
maximum concentration of D-dimer concentration 
(D-Dmax) and the rate of increase in D-dimer concentra-
tions released from the clot (D-Drate) were determined in 
each subject. The experiment was usually stopped after 
80–120  min when the fibrin gel collapsed under the 
pressure.
Follow‑up
The primary endpoint was cardiovascular death. The 
length of follow-up was censored at the time of death. 
Follow-up by telephone was conducted between July 
2017 and January 2018. The family of the deceased 
patient was asked about the cause of death. In the case 
of incomplete medical record data or loss to clinical fol-
low-up, patient status was assessed in March 2019 using 
the National Mortality Registry maintained by the State 
Systems Department of Ministry of Digital Affairs. The 
International Statistical Classification of Diseases 10 
(ICD-10) codes I70.9, I25.0, I25.9, and I11.0 were clas-
sified to be cardiovascular death. In the case of ICD-10 
code R99, the correct classification of death was based on 
additional clinical data. The secondary endpoint was all-
cause death.
Statistical analysis
Continuous data were presented as medians (interquartile 
range, IQR) and were compared using the Mann–Whit-
ney U test. Categorial data were presented as numbers 
(percentages). To test the differences in proportions 
between two groups, Fisher’s exact test was used. Contin-
uous variables (peak thrombin, ΔAbsmax,  Ks, compaction, 
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CLT,  t50%, D-Dmax, and D-Drate) were dichotomized using 
the cut-off values found in the analysis of receiver operat-
ing curves (ROC), which optimally classified the clinical 
endpoint, as described previously [37]. Multivariable Cox 
proportional hazards survival regression, after adjust-
ment for age and sex, was used to investigate the effect 
of high peak thrombin, high ΔAbsmax, low  Ks, high com-
paction, prolonged CLT, prolonged  t50%, high D-Dmax, 
and low D-Drate, on clinical outcomes. The results were 
presented as hazard ratios (HR) with 95% confidence 
interval (CI). The HR were additionally adjusted for pos-
sible confounding factors, identified in the comparison 
analysis of two groups. Kaplan–Meier survival curves 
were drawn. Six factors (age > 65 years, previous cardio-
vascular event, CRP level > 3 mg/l, hypercholesterolemia 
defined as LDL > 1.8  mmol/l or treatment with statins, 
D-Dmax and peak thrombin) were analyzed for the associ-
ation with the cardiovascular mortality in the univariate 
logistic regression model. The Nagelkerke  R2 represented 
the contribution of D-Dmax and peak thrombin to the 
variation in cardiovascular mortality. Factors, which sig-
nificantly associated with cardiovascular mortality in the 
univariate regression model, were included in the multi-
variable logistic regression model. Results of the regres-
sion model were presented as odds ratio (OR) with 95% 
CI. To address the problem of multiple comparisons, the 
results were controlled with the Benjamini–Hochberg 
procedure. If continuous variables correlated with Spear-
man’s correlation coefficient > 0.5, only one of them was 
included in the multivariable regression model. A two-
sided p-value of < 0.05 was considered statistically signifi-
cant. No formal sample size calculation was performed, 
as the number of patients included in the original study 
was fixed [12]. We performed a post hoc power calcula-
tion based on a 12% event rate, HR of 5.4, with the dis-
tribution of patients in the subgroups 20%/80%. Given 
these estimates, and with a significance level set at 5%, a 
post hoc power of 78% was found for D-Dmax. Statistical 
analyses were performed using IBM SPSS Statistics for 
Windows, Version 25.0. (Armonk, NY: IBM Corp.). The 
Benjamini–Hochberg procedure was applied in R [38]. 
Figures were prepared using GraphPad Prism (version 




A total of 156 patients with T2DM (87 men and 69 
women) were enrolled. At the time of enrollment, 
median period since diagnosis of T2DM was 5.0 (IQR, 
2.0–10.0) years, while the HbA1C levels ranged from 
5.2 to 12.6 (median, 6.5) %. The patients were mostly 
(60.3%) treated with biguanides, while 26.3% of patients 
received insulin. A history of cardiovascular events was 
recorded in 67.3% of patients, including 64.1% with 
CAD.
Patient characteristics during follow‑up with respect 
to cardiovascular death in the entire study group
The median length of follow-up was 72 (68–74) months. 
Twenty-three (14.7%) patients were lost to follow-up. 
Final analysis involved 133 patients, 79 men and 54 
women, aged 43.0–83.0 (median 66.0) years. During 
follow-up, 16 patients (12.0%) died from cardiovascular 
causes (2.18 per 100 patient-years). Patients who died 
from cardiovascular causes did not differ from the survi-
vors in terms of demographic data and time since T2DM 
diagnosis, but they more commonly had nephropathy at 
baseline and less commonly were treated with metformin 
when compared to the survivors (Table 1). Despite simi-
lar HbA1c, patients who died from cardiovascular causes 
tended to have lower fasting glucose levels when com-
pared with the remaining patients (Table 2). Patients who 
died from cardiovascular causes had lower total and LDL-
cholesterol and higher CRP when compared with the 
remaining patients (Table  2). Patients with LDL-choles-
terol above the a median, i.e. ≥ 2.3 mmol/l, did not differ 
from the remaining subjects in regard to the parameters 
of clot structure and function. The baseline fibrinogen 
concentration, tPA and PAI-1 antigen, α2-antiplasmin 
and TAFI activity, as well as thrombomodulin antigen 
did not differ between patients who died from cardio-
vascular causes and the survivors (Table  2). Analysis of 
several variables describing plasma fibrin clot structure 
and function showed that the clot turbidity, permeabil-
ity, compaction, and lysability, represented by CLT, were 
comparable in patients who died from cardiovascular 
causes and the survivors (Table  2). Patients who died 
from cardiovascular causes had higher D-Dmax and lower 
D-Drate when compared with the survivors (Table 2). The 
absolute difference in D-Drate between those groups cor-
responds with the standardized effect size of 0.68, and it 
is statistically significant in the Mann–Whitney’s test.
Correlations between the investigated parameters 
in the entire study group
The D-Dmax correlated with ∆Abs (r = 0.432, p < 0.001), 
 Ks (r = − 0.496, p < 0.001), compaction (r = − 0.446, 
p < 0.001), CLT (r = − 0.463, p < 0.001), and  t50% 
(r = 0.518, p < 0.001), but not with peak thrombin 
(r = 0.14, p = 0.10). The correlations between D-Dmax 
and CRP, and between D-Drate and CRP, were weak 
(r = 0.208, p = 0.020, and r = − 0.208, p = 0.020, 
respectively).
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Predictors of cardiovascular mortality in the entire study 
group
Based on the ROC curves, D-Dmax > 4.26  mg/l was 
regarded as a decreased value and D-Drate < 0.07  mg/l/
min was considered as decreased. At baseline, increased 
D-Dmax was noted in 25 patients (18.8%), while decreased 
D-Drate was observed in 54 (40.6%) patients. Cardiovas-
cular deaths occurred more frequently in patients with 
increased maximum concentration of D-dimer released 
from the clot during lysis induced by tPA (D-Dmax) and 
decreased  rate of D-dimer release (D-Drate, Table  3, 
Fig. 1a, b). Another predictor of cardiovascular death was 
increased peak thrombin (Table 3, Fig. 1c). Based on the 
ROC curves, increased peak thrombin > 283.5  nM was 
noted in 23 (17.3%) patients at baseline. Adjustment for 
cardiovascular disease history prior to the study enroll-
ment, nephropathy, or treatment with metformin did not 
influence the hazard ratios (Table 3). In univariate regres-
sion model analysis, the high D-Dmax was responsible for 
13% variation in cardiovascular mortality (OR 5.88, 95% 
CI 1.94–17.79), while high peak thrombin accounting for 
10% of that variation (OR 4.91, 95% CI 1.60–15.04). Since 
D-Drate correlated with D-Dmax (r = − 0.536, p < 0.001), 
only D-Dmax was included in the regression model. The 
multivariable model including increased D-Dmax, along 
with traditional risk factors for cardiovascular mortal-
ity such as age > 65  years, cardiovascular events prior 
to study enrollment (myocardial infarction or stroke), 
and inflammatory state represented by CRP > 3  mg/l, 
accounted for 37% variation in cardiovascular death 
(Fig.  2a). When increased D-Dmax was replaced in the 
model by increased peak thrombin, the explained vari-
ation in cardiovascular mortality was 42% (Fig. 2b). The 
Benjamini–Hochberg procedure controls did not affect 
results obtained in the multivatiate regression model. 
Despite the fact that D-Dmax correlated with many of the 
investigated parameters as presented above, only D-Dmax 
was found to be a predictor of cardiovascular death.  
Predictors of cardiovascular mortality in the subgroup 
of patients with prior cardiovascular disease
When T2DM patients with a history of cardiovascu-
lar disease prior to enrollment were analyzed separately 
(n = 86, 64.7%), 13 (15.1%) deaths were recorded. The 
Table 1 Baseline characteristics of  type 2 diabetes mellitus (T2DM)  patients divided according to  the  cardiovascular 
death
Continuous data are presented as the median (interquartile range) and compared using Mann–Whitney test. Categorical data are presented as number (percentages) 
and compared using Fisher’s exact test
ACEI angiotensin converting enzyme inhibitor
Variable Non‑survivors (n = 16) Survivors (n = 117) p‑value
Age, years 70.5 (64.0–77.0) 65.0 (60.0–71.0) 0.09
Female gender, n (%) 5 (31.3) 49 (41.9) 0.59
Current smoking, n (%) 2 (12.5) 10 (8.6) 0.64
Body-mass index, kg/m2 31.4 (26.2–34.2) 31.6 (28.4–35.4) 0.34
Obesity, n (%) 10 (62.5) 80 (68.4) 0.78
Time since T2DM diagnosis, years 8.0 (2.0–13.0) 5.0 (2.0–10.0) 0.43
Comorbidities, n (%)
 Arterial hypertension 14 (87.5) 112 (95.7) 0.20
 Coronary artery disease 13 (62.3) 73 (62.4) 0.17
 Previous myocardial infarction 6 (37.5) 19 (16.2) 0.08
 Previous stroke 3 (18.8) 4 (3.4) 0.04
 Nephropathy 6 (37.5) 17 (14.5) 0.03
 Neuropathy 4 (25.0) 20 (17.1) 0.49
 Retinopathy 4 (25.0) 17 (14.5) 0.28
Medications, n (%)
 Acetylsalicylic acid 13 (81.3) 92 (78.6) 1.00
 Statin 13 (81.3) 93 (79.5) 1.00
 ACE-I 10 (62.5) 81 (69.2) 0.58
 β-blocker 14 (87.5) 91 (77.8) 0.52
 Metformin 5 (31.3) 75 (64.1) 0.02
 Sulfonylourea 9 (56.3) 47 (40.2) 0.28
 Insulin 6 (37.5) 27 (23.1) 0.23
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Table 2 Baseline laboratory investigations of type 2 diabetes mellitus patients divided according to the cardiovascular 
death
Data are presented as the median (interquartile range) and compared using Mann–Whitney test
HbA1c glycated hemoglobin, LDL low-density lipoprotein, HDL high-density lipoprotein, tPA tissue plasminogen activator, PAI plasminogen activator inhibitor 1, 
TAFI thrombin-activatable fibrinolysis inhibitor, Ks permeability coefficient, ∆Abs maximum absorbance at plateau, t50% the time required for a 50% decrease in clot 
turbidity, CLT clot lysis time, D-Dmax maximum D-dimer concentrations, D-Drate maximum rates of increase in D-dimer levels
Variable Non‑survivors (n = 16) Survivors (n = 117) P‑value
Basic
 HbA1c, % 6.7 (6.2–8.5) 6.4 (6.1–7.1) 0.25
 Fasting glucose, mmol/l 5.0 (4.2–6.5) 6.0 (5.3–7.4) 0.06
 Creatinine, µmol/l 82.0 (77.0–113.5) 81.0 (65.0–96.0) 0.17
 Total cholesterol, mmol/l 3.4 (3.3–4.4) 4.3 (3.6–5.0) 0.03
 LDL-cholesterol, mmol/l 1.7 (1.4–2.4) 2.4 (1.9–3.0) 0.01
 HDL-cholesterol, mmol/l 1.2 (1.0–1.5) 1.3 (1.1–1.6) 0.30
 Triglycerides, mmol/l 1.0 (0.9–1.6) 1.3 (1.0–1.8) 0.22
 High-sensitivity C-reactive protein, mg/l 3.3 (1.9–6.0) 1.9 (1.0–3.4) 0.04
Coagulation parameters
 Fibrinogen, g/l 3.2 (2.8–3.5) 3.0 (2.6–3.5) 0.32
 Peak thrombin, nM 253.5 (212.0–289.5) 228.0 (201.0–268.0) 0.17
 Plasminogen activity, % 105.5 (88.5–115.5) 105.0 (98.0–117.0) 0.48
 tPA antigen, ng/ml 11.8 (9.3–15.6) 11.2 (10.0–13.2) 0.49
 PAI-1 antigen, ng/ml 32.1 (29.5–37.1) 32.1 (29.5–37.1) 0.88
 α2-antiplasmin activity, % 115.0 (101.0–121.0) 115.0 (101.0–121.0) 0.16
 TAFI activity, % 97.5 (89.0–106.0) 97.5 (89.0–106.0) 0.72
 Thrombomodulin antigen, ng/ml 3.1 (2.3–3.6) 3.01 (2.3–3.6) 0.91
Fibrin clot properties
 Lag phase, s 42.5 (40.0–44.5) 43.0 (40.0–46.0) 0.67
 ∆Abs, 405 nm 0.825 (0.800–0.860) 0.810 (0.770–0.850) 0.26
 Ks, × 10–9  cm2 7.0 (6.2–7.3) 7.1 (6.6–7.7) 0.13
 Compaction, % 44.0 (39.5–46.0) 44.0 (40.0–49.0) 0.47
 CLT, min 88.0 (79.0–104.5) 95.0 (82.0–105.0) 0.45
 t50%, min 10.15 (9.60–10.95) 9.8 (9.0–10.4) 0.06
 D-Dmax, mg/l 4.18 (3.77–4.48) 3.85 (3.60–4.09) 0.01
 D-Drate, mg/l/min 0.069 (0.064–0.071) 0.070 (0.068–0.073) 0.02
Table 3 Predictors of cardiovascular and all-cause mortality in type 2 diabetes mellitus patients
D-Dmax, D-Drate and peak thrombin were dichotomized using the cut-off value found in the receiver operating curves that optimally classified the cardiovascular and 
all-cause death. Data were presented as hazard ratio (HR) with 95% confidence interval (CI) calculated in multivariable Cox proportional hazards survival regression
D-Dmax maximum concentration of D-dimer concentration released from the clot during lysis induced by tissue plasminogen activator, D-Drate maximum rates of 
increase in D-dimer levels
Hazard ratios adjusted for sex and age (*); for sex, age and cardiovascular disease history (**); for sex, age and nephropathy (***); for sex, age and metformin (****)
Predictor HR* (95% CI) HR** (95% CI) HR*** (95% CI) HR**** (95% CI)
Cardiovascular mortality
 D-Dmax > 4.26 mg/l 5.43 (1.99–14.79) 5.79 (2.08–16.16) 5.08 (1.85–13.9) 6.85 (1.85–13.90)
 D-Drate < 0.07 mg/l/min 2.97 (1.07–8.23) 4.52 (1.47–13.86) 3.49 (1.24–9.82) 3.77 (1.33–10.69)
 Peak thrombin > 283.5 nM 5.65 (2.07–15.51) 9.23 (2.97–28.86) 6.50 (2.34–18.18) 7.10 (2.52–20.05)
All-cause mortality
 D-Dmax > 4.26 mg/l 3.48 (1.45–8.39) 3.61 (1.49–8.77) 3.45 (1.43–8.30) 3.85 (1.57–9.44)
 D-Drate < 0.07 mg/l/min 3.29 (1.31–8.28) 3.97 (1.50–10.46) 3.28 (1.03–8.24) 3.06 (1.18–7.90)
 Peak thrombin > 283.5 nM 6.54 (2.78–15.35) 9.66 (3.72–25.09) 6.69 (2.85–15.69) 7.91 (3.28–19.07)
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predictors of cardiovascular mortality were D-Dmax (HR 
6.18, 95% CI 2.02–18.96, Fig.  1d) and D-Drate (HR 8.98, 
95% CI 2.99–26.96, Fig. 1e), as well as peak thrombin (HR 
5.35, 95% CI 1.62–17.72, Fig. 1f ).
Predictors of all‑cause mortality in the entire study group
During follow-up, all-cause death was recorded in 22 
patients (16.5%, 2.99 per 100 patient-years), indicat-
ing 6 non-cardiovascular fatal events. Non-survivors 
were older (72.0 [66.0–77.0] vs. 65.0 [59.0–71.0] years, 
p = 0.004) when compared with survivors. Other demo-
graphic data, time since T2DM diagnosis, comorbidities, 
medications, and laboratory investigations, including 
fibrin properties, did not differ between the two groups. 
Similar to cardiovascular mortality, Kaplan–Meier 
curves showed that all-cause mortality was predicted by 
high D-Dmax, low D-Drate, and high peak thrombin with 
similar cut-offs and HR with 95% CI as for cardiovascular 
mortality, before and after adjustment for sex, age, car-
diovascular disease history, nephropathy, and metformin 
treatment (Table 3).
Comparison of patients who died from non‑cardiovascular 
vs. cardiovascular causes
When compared with patients who died from cardiovas-
cular causes (n = 16, 12%), patients who died from non-
cardiovascular causes (n = 6, 4.5%) were less frequently 
treated with β-blockers (2 [33.3] vs. 14 [87.5], p = 0.03) 
and had a higher concentration of LDL-cholesterol by 
0.9  mmol/l (p = 0.03), although the frequency of treat-
ment with statin was comparable between groups. More-
over, patients who died from non-cardiovascular causes 
had 11.4% increased clot compaction (p = 0.008), 7.4% 
shorter  t50% (p = 0.049), and tended to have lower D-Dmax 
Fig. 1 Kaplan–Meier curves showing probability of survival in diabetic patients (a–c) and in diabetic patients with cardiovascular disease (d–f) with 
increased maximum D-dimer concentration (D-Dmax), or decreased rate of D-dimer (D-Drate) released during clot lysis, or increased peak thrombin 
generated, as compared with the remainder. Cut-offs were estimated based on the receiver operating curves. The D-Dmax > 4.26 mg/l was regarded 
as increased in all diabetic patients, while D-Dmax > 4.25 mg/l was regarded as increased in diabetic patients with cardiovascular disease; in both 
groups D-Drate < 0.07 mg/l/min was considered to be decreased, and peak thrombin > 283.5 nM was regarded as increased. P-values were calculated 
in the Mantel-Cox test
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(p = 0.08) when compared with patients who died from 
cardiovascular causes.
Discussion
To the best of our knowledge, this study is the first to 
evaluate the association between plasma fibrin clot prop-
erties and cardiovascular mortality during long-term 
follow-up of T2DM patients. Among several fibrin vari-
ables tested at enrollment, only D-Dmax and D-Drate were 
identified to be independent predictors of cardiovascular 
mortality in T2DM patients. These fibrin-related param-
eters (not associated with plasma fibrinogen concentra-
tion), in addition to advanced age, prior cardiovascular 
disease, and elevated CRP levels, helped to identify the 
risk of cardiovascular death. These associations were 
even more pronounced when patients with concomitant 
T2DM and prior cardiovascular disease were analyzed.
Assay utilizing D‑dimer concentrations: clinical relevance, 
possible mechanisms, and perspectives for future studies
Two measures of fibrin clot architecture determined in 
the assay introduced by Collet et al. in 1999 [35] indi-
cate slightly different features of the clot. The D-Dmax 
indicates the fibrin mass subjected to lysis by rtPA, 
while the D-Drate reflects the ability of rtPA to pen-
etrate into the fibrin clots. To understand the clinical 
relevance of these two parameters, it should be clear 
that opposite results associate with unfavorable fibrin 
clot characteristics: increased D-Dmax and decreased 
D-Drate. In contrast to turbidity, where fibrin clot for-
mation and degradation take place simultaneously 
[39], D-Drate is the measure of tPA-induced degrada-
tion of the previously prepared plasma clots, generated 
in the presence of thrombin and calcium. The assay in 
which D-Drate or D-Dmax are evaluated may reflect the 
situation in which accumulating intravascular fibrin 
is exposed to exogenous tPA. For example, damage to 
the atherosclerotic plaque, which is rich in fibrin [40], 
results in the formation of fibrin on the surface of the 
exposed site [41]. A modified version of the method 
described by Collet et  al. [35, 36] might be consid-
ered as a method to measure fibrin removal from the 
atherosclerotic plaques. We observed the association 
of D-Drate and/or D-Dmax with cardiovascular events 
also in our previous studies [36, 42]. Cardiovascular 
mortality was not predicted by other fibrinolytic tests 
(CLT and  t50%) in which much lower concentrations of 
rtPA were applied, similar to those encountered during 
thrombolysis [43]. Results from our study support the 
use of a comprehensive set of plasma fibrin clot assays 
over the single test to better characterize fibrin clots in 
a given clinical setting.
The mechanisms behind impaired fibrinolysis in T2DM 
patients, including non-survivors during long-term fol-
low-up, remain unclear despite extensive experimental 
efforts over the last decade [44]. Adjustment for poten-
tial clinical confounders, such as metformin treatment 
[45, 46], did not influence the results. Higher cardiovas-
cular mortality was not attributed to the differences in 
fibrinogen concentration, the most important modula-
tor of fibrin clot properties [8, 47], or PAI-1, or TAFI. It 
is hypothesized that post-translational modifications of 
fibrinogen (i.e. glycation and oxidation) are involved [48, 
49].
Our study opens the discussion about the fibrin-
targeted pharmacotherapy, which could improve the 
clinical outcomes in T2DM patients. Antithrombotic 
agents, such as aspirin monotherapy or in combina-
tion with low-dose rivaroxaban, have a favorable impact 
on cardiovascular mortality in T2DM [50]. The same 
agents can improve fibrin clot properties, including the 
acceleration of fibrinolysis [51, 52]. Prevention of mor-
tality among T2DM patients receiving antithrombotic 
medications might be partly attributed to improved 
fibrin clot phenotype. Larger studies, including patients 
receiving antithrombotic agents, are needed to validate 
Fig. 2 Associations of increased maximum concentration of D-dimer 
released during clot lysis (D-Dmax), peak thrombin and cardiovascular 
risk factors with cardiovascular mortality. Cardiovascular risk factors 
included: age > 65 years, prior cardiovascular disease, C-reactive 
protein > 3 mg/l. The D-Dmax and peak thrombin were dichotomized 
using the cut-off value found in the receiver operating curves which 
optimally classified the cardiovascular death. A D-Dmax > 4.26 mg/l 
and peak thrombin > 283.5 nM were regarded as increased. Squares 
represent odds ratio (OR) estimates, and horizontal lines represent 
95% confidence intervals (CI), found in the multivariable regression 
analysis. CV denotes cardiovascular; CRP, C-reactive protein
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this intriguing hypothesis. Furthermore, it remains 
unclear whether the cardiovascular protective role of 
sodium-glucose cotransporter inhibitors or glucagon-
like peptide-1 receptor agonists in T2DM is related to an 
improvement in fibrin clot properties.
Other predictors of cardiovascular death: thrombin 
generation and CRP
Thrombin generation, as a potential predictor of cardio-
vascular mortality in T2DM, deserves a comment, given 
the contradictory results between the Ludwigshafen Risk 
and Cardiovascular Health (LURIC) [53] and Gutenberg 
Health Studies [54]. Our study provides data in favor 
of the positive association of thrombin generation and 
cardiovascular mortality in T2DM. Elevated CRP was 
another predictor of cardiovascular death in our study. 
Previously, elevated CRP level has been reported to be 
a predictor of cardiovascular and all-cause mortality 
in T2DM patients [55], although it has not been found 
to independently predict fibrin clot lysis in T2DM [9]. 
We speculate that elevated CRP increases the negative 
impact of dense fibrin clot formation, which are resistant 
to lysis in T2DM, although the mechanisms of this link 
remain elusive.
Study limitations
Our study has several limitations. Firstly, the number 
of study participants was limited; however, the study 
was sufficiently powered to detect associations between 
plasma fibrin clot and cardiovascular events. The small 
sample size may have impeded adequate identification of 
possible confounding factors on the results. Non-survi-
vors may have been a group with more advanced co-mor-
bidities which could be reflected by a higher percentage 
of patients with nephropathy and prior stroke, when 
compared with survivors. Nevertheless, adjustment for 
previous cardiovascular events and nephropathy did not 
significantly influence the hazard ratios of investigated 
parameters for cardiovascular death. Larger studies in 
this area could allow for better distribution of comorbidi-
ties between the studied groups.
Secondly, antidiabetic medications being used and gly-
cemic control, as reflected by HbA1c, were not assessed 
during follow-up. Because the median time since T2DM 
diagnosis at baseline was 5  years, we suspect that the 
impact of disease duration outweighed the effects of pos-
sible periods of inadequate glycemic control during that 
time [12].
Thirdly, use of the modified assay by Collet et  al. in 
clinical practice is limited due to lack of standardization 
and the fact that it is a time-consuming protocol, requir-
ing hands-on laboratory expertise to obtain reproducible 
results [35]. Our findings clearly show that further efforts 
to optimize the determination method of fibrin clot den-
sity and lysability in real-life patients are worthwhile as 
they might be clinically relevant in formulating a progno-
sis related to cardiovascular mortality. Another limitation 
of the study was that our analysis included only one of 
the thrombin generation parameters, i.e. peak throm-
bin. Although endogenous thrombin potential could add 
some extra information, both parameters are well corre-
lated with each other [56].
Finally, we did not analyze specific cardiovascular 
events during follow-up since we focused on death as the 
single hard endpoint.
Conclusions
In summary, our current study shows that the formation 
of denser clots, which are resistant to fibrinolysis, may 
predict cardiovascular mortality in T2DM.
Abbreviations
ΔAbs: Maximum absorbance at plateau; CAD: Coronary artery disease; CI: 
Confidence interval; CLT: Clot lysis time; CRP: C-reactive protein; D-Dmax: Maxi-
mum concentration of D-dimer released during tissue plasminogen activator 
induced clot lysis; D-Drate: Rate of increase in D-dimer concentration released 
during tissue plasminogen activator-induced clot lysis; HbA1c: Glycated 
hemoglobin; HR: Hazard ratio; Ks: Darcy’s constant or clot permeability; LDL: 
Low-density lipoprotein; OR: Odds ratio; PAI-1: Plasminogen activator inhibitor 
1; ROC: Receiver operating curve; rtPA: Recombinant tissue plasminogen acti-
vator; t50%: Time required for a 50% decrease in clot turbidity; TAFI: Thrombin-
activatable fibrinolysis inhibitor; tPA: Tissue plasminogen activator.
Acknowledgements
We would like to thank Dr. Joanna Natorska, PhD and Dr. Michal Zabczyk, PhD 
for technical support.
Authors’ contributions
AHB contributed to the work by acquisition of data, analysis and interpretation 
of data, as well as writing of the manuscript. MK contributed to the work by 
acquisition of data, writing and revising the manuscript. MP provided statisti-
cal analysis of the data. DP and MB contributed to the work by acquisition 
of data and revised the manuscript. AU made substantial contributions to con-
ception and design of the study, analysis and interpretation of data, revision of 
the manuscript and final approval of the version to be published. All authors 
read and approved the final manuscript.
Funding
None.
Availability of data and materials
The datasets used and/or analyzed during the current study are available from 
the corresponding author on reasonable request.
Ethics approval and consent to participate
The study complied with the principles of Good Clinical Practice rules and was 
approved by the Regional Medical Chamber Ethics Committee. Each study 




The authors declare that they have no competing interests.
Page 10 of 11Bryk et al. Cardiovasc Diabetol           (2021) 20:47 
Author details
1 Department of Endocrinology, Jagiellonian University Medical College, 
Krakow, Poland. 2 John Paul II Hospital, Krakow, Poland. 3 Department 
of Epidemiology and Population Studies, Institute of Public Health, Faculty 
of Health Sciences, Jagiellonian University Medical College, Krakow, Poland. 
4 Unit of Experimental Cardiology and Cardiac Surgery, Faculty of Medicine 
and Health Sciences, Andrzej Frycz Modrzewski Krakow University, Krakow, 
Poland. 5 Clinic of Cardiac Transplantation and Mechanical Circulatory Support, 
Department of Heart Diseases, Wroclaw Medical University, Wrocław, Poland. 
6 Institute of Cardiology, Jagiellonian University Medical College, 80 Pradnicka 
St., 31-202 Krakow, Poland. 
Received: 24 October 2020   Accepted: 29 January 2021
References
 1. Saeedi P, Petersohn I, Salpea P, Malanda B, Karuranga S, Unwin N, et al. 
Global and regional diabetes prevalence estimates for 2019 and projec-
tions for 2030 and 2045: Results from the International Diabetes Federa-
tion Diabetes Atlas, 9th edition. Diabetes Res Clin Pract. 2019;157:107843. 
https ://doi.org/10.1016/j.diabr es.2019.10784 3.
 2. Rawshani A, Rawshani A, Franzén S, Eliasson B, Svensson AM, Miftaraj M, 
et al. Mortality and cardiovascular disease in type 1 and type 2 diabetes. 
N Engl J Med. 2017;376:1407–18. https ://doi.org/10.1056/NEJMo a1608 
664.
 3. Einarson TR, Acs A, Ludwig C, Panton UH. Prevalence of cardiovascular 
disease in type 2 diabetes: a systematic literature review of scientific 
evidence from across the world in 2007–2017. Cardiovasc Diabetol. 
2018;17:83. https ://doi.org/10.1186/s1293 3-018-0728-6.
 4. Niedziela J, Hiczkiewicz J, Kleinrok A, Pączek P, Leszek P, Lelonek M, 
et al. Prevalence, characteristics, and prognostic implications of type 2 
diabetes in patients with myocardial infarction: the Polish Registry of 
Acute Coronary Syndromes (PL-ACS) annual 2018 report. Kardiol Pol. 
2020;78:243–6. https ://doi.org/10.33963 /KP.15189 .
 5. Leander K, Blombäck M, Wallén H, He S. Impaired fibrinolytic capacity and 
increased fibrin formation associate with myocardial infarction. Thromb 
Haemost. 2012;106:1092–9. https ://doi.org/10.1160/TH11-11-0760.
 6. Zalewski J, Bogaert J, Sadowski M, Woznicka O, Doulaptsis K, Ntoump-
anaki M, et al. Plasma fibrin clot phenotype independently affects 
intracoronary thrombus ultrastructure in patients with acute myocardial 
infarction. Thromb Haemost. 2015;113:1258–69. https ://doi.org/10.1160/
TH14-09-0801.
 7. Undas A, Wiek I, Stepien E, Zmudka K, Tracz W. Hyperglycemia is associ-
ated with enhanced thrombin formation, platelet activation, and fibrin 
clot resistance to lysis in patients with acute coronary syndrome. Diabe-
tes Care. 2008;31:1590–5. https ://doi.org/10.2337/dc08-0282.
 8. Dunn EJ, Ariëns RAS, Grant PJ. The influence of type 2 diabetes on fibrin 
structure and function. Diabetologia. 2005;48:1198–206. https ://doi.
org/10.1007/s0012 5-005-1742-2.
 9. Hess K, Alzahrani SH, Price JF, Strachan MW, Oxley N, King R, et al. Hypofi-
brinolysis in type 2 diabetes: the role of the inflammatory pathway and 
complement C3. Diabetologia. 2014;57:1737–41. https ://doi.org/10.1007/
s0012 5-014-3267-z.
 10. Pieters M, Covic N, Loots DT, van der Westhuizen FH, van Zyl DG, Rheeder 
P, et al. The effect of glycaemic control on fibrin network structure of 
type 2 diabetic subjects. Thromb Haemost. 2006;96:623–9. https ://doi.
org/10.1160/TH06-07-0390.
 11. Jörneskog G, Egberg N, Fagrell B, Fatah K, Hessel B, Johnsson H, et al. 
Altered properties of the fibrin gel structure in patients with IDDM. 
Diabetologia. 1996;39:1519–23.
 12. Konieczynska M, Fil K, Bazanek M, Undas A. Prolonged duration of type 
2 diabetes is associated with increased thrombin generation, prothrom-
botic fibrin clot phenotype and impaired fibrinolysis. Thromb Haemost. 
2014;111:685–93. https ://doi.org/10.1160/TH13-07-0566.
 13. Bochenek M, Zalewski J, Sadowski J, Undas A. Type 2 diabetes as a modi-
fier of fibrin clot properties in patients with coronary artery disease. J 
Thromb Thrombolysis. 2013;35:264–70. https ://doi.org/10.1007/s1123 
9-012-0821-8.
 14. Neergaard-Petersen S, Hvas A-M, Kristensen SD, Grove EL, Larsen SB, 
Phoenix F, et al. The influence of type 2 diabetes on fibrin clot prop-
erties in patients with coronary artery disease. Thromb Haemost. 
2014;112:1142–50. https ://doi.org/10.1160/TH14-05-0468.
 15. Alessi MC, Juhan-Vague I. PAI-1 and the metabolic syndrome: links, 
causes, and consequences. Arterioscler Thromb Vasc Biol. 2006;26:2200–
7. https ://doi.org/10.1161/01.ATV.00002 42905 .41404 .68.
 16. Hori Y, Gabazza EC, Yano Y, Katsuki A, Suzuki K, Adachi Y, et al. Insulin 
resistance is associated with increased circulating level of thrombin-acti-
vatable fibrinolysis inhibitor in type 2 diabetic patients. J Clin Endocrinol 
Metab. 2002;87:660–5. https ://doi.org/10.1210/jcem.87.2.8214.
 17. Dunn EJ, Philippou H, Ariëns RAS, Grant PJ. Molecular mechanisms 
involved in the resistance of fibrin to clot lysis by plasmin in subjects 
with type 2 diabetes mellitus. Diabetologia. 2006;49:1071–80. https ://doi.
org/10.1007/s0012 5-006-0197-4.
 18. Svensson J, Bergman A-C, Adamson U, Blombäck M, Wallén H, Jörneskog 
G. Acetylation and glycation of fibrinogen in vitro occur at specific 
lysine residues in a concentration dependent manner: a mass spec-
trometric and isotope labeling study. Biochem Biophys Res Commun. 
2012;421:335–42. https ://doi.org/10.1016/j.bbrc.2012.03.154.
 19. Ajjan RA, Gamlen T, Standeven KF, Mughal S, Hess K, Smith KA, et al. Dia-
betes is associated with posttranslational modifications in plasminogen 
resulting in reduced plasmin generation and enzyme-specific activity. 
Blood. 2013;122:134–42. https ://doi.org/10.1182/blood -2013-04-49464 1.
 20. Wittbrodt E, Bhalla N, Andersson K, Qi S, Dong L, Cavender MA, et al. 
Assessment of the high risk and unmet need in patients with CAD and 
type 2 diabetes (ATHENA): US healthcare resource utilization, cost and 
burden of illness in the Diabetes Collaborative Registry. Endocrinol Diab 
Metab. 2020;3:e00133. https ://doi.org/10.1002/edm2.133.
 21. Pignatelli P, Menichelli D, Pastori D, Violi F. Oxidative stress and cardio-
vascular disease: new insights. Kardiol Pol. 2018;76:713–22. https ://doi.
org/10.5603/KP.a2018 .0071.
 22. Ramanathan R, Gram JB, Sidelmann JJ, Dey D, Kusk MW, Nørgaard BL, 
et al. Sex difference in fibrin clot lysability: association with coronary 
plaque composition. Thromb Res. 2019;174:129–36. https ://doi.
org/10.1016/j.throm res.2018.12.020.
 23. Zhang L, Xu C, Liu J, Bai X, Li R, Wang L, et al. Baseline plasma fibrinogen is 
associated with haemoglobin A1c and 2-year major adverse cardiovas-
cular events following percutaneous coronary intervention in patients 
with acute coronary syndrome: a single-centre, prospective cohort 
study. Cardiovasc Diabetol. 2019;18:1–12. https ://doi.org/10.1186/s1293 
3-019-0858-5.
 24. Li M, Duan L, Cai YL, Li HY, Hao BC, Chen JQ, et al. Growth differentiation 
factor-15 is associated with cardiovascular outcomes in patients with 
coronary artery disease. Cardiovasc Diabetol. 2020;19:1–12. https ://doi.
org/10.1186/s1293 3-020-01092 -7.
 25. Sumaya W, Wallentin L, James SK, Siegbahn A, Gabrysch K, Himmelmann 
A, et al. Impaired fibrinolysis predicts adverse outcome in acute coronary 
syndrome patients with diabetes: a PLATO sub-study. Thromb Haemost. 
2020;120:412–22. https ://doi.org/10.1055/s-0039-17010 11.
 26. Neergaard-Petersen S, Larsen SB, Grove EL, Kristensen SD, Ajjan RA, Hvas 
AM. Imbalance between fibrin clot formation and fibrinolysis predicts 
cardiovascular events in patients with stable coronary artery disease. 
Thromb Haemost. 2020;120:75–82. https ://doi.org/10.1055/s-0039-17008 
73.
 27. Cosentino F, Grant PJ, Aboyans V, Bailey CJ, Ceriello A, Delgado V, 
et al. 2019 ESC guidelines on diabetes, pre-diabetes, and cardiovas-
cular diseases developed in collaboration with the EASD. Eur Heart J. 
2020;41:255–323. https ://doi.org/10.1093/eurhe artj/ehz48 6.
 28. Stepień E, Plicner D, Branicka A, Stankiewicz E, Pazdan A, Sniezek-
Maciejewska M, et al. Factors influencing thrombin generation measured 
as thrombin-antithrombin complexes levels and using calibrated 
automated thrombogram in patients with advanced coronary artery 
disease. Pol Arch Med Wewn. 2007;117:297–305. https ://doi.org/10.20452 
/pamw.162.
 29. Mills JD, Ariëns RAS, Mansfield MW, Grant PJ. Altered fibrin clot structure 
in the healthy relatives of patients with premature coronary artery dis-
ease. Circulation. 2002;106:1938–42.
 30. Undas A, Szułdrzynski K, Stepien E, Zalewski J, Godlewski J, Tracz W, et al. 
Reduced clot permeability and susceptibility to lysis in patients with 
acute coronary syndrome: effects of inflammation and oxidative stress. 
Page 11 of 11Bryk et al. Cardiovasc Diabetol           (2021) 20:47  
•
 
fast, convenient online submission
 •
  
thorough peer review by experienced researchers in your field
• 
 
rapid publication on acceptance
• 
 
support for research data, including large and complex data types
•
  
gold Open Access which fosters wider collaboration and increased citations 
 
maximum visibility for your research: over 100M website views per year •
  At BMC, research is always in progress.
Learn more biomedcentral.com/submissions
Ready to submit your research ?  Choose BMC and benefit from: 
Atherosclerosis. 2008;196:551–7. https ://doi.org/10.1016/j.ather oscle rosis 
.2007.05.028.
 31. Undas A, Podolec P, Zawilska K, Pieculewicz M, Jedliński I, Stgpień E, 
et al. Altered fibrin clot structure/function in patients with cryptogenic 
ischemic stroke. Stroke. 2009;40:1499–501. https ://doi.org/10.1161/
STROK EAHA.108.53281 2.
 32. Undas A, Slowik A, Wolkow P, Szczudlik A, Tracz W. Fibrin clot properties 
in acute ischemic stroke: relation to neurological deficit. Thromb Res. 
2010;125:357–61. https ://doi.org/10.1016/j.throm res.2009.11.013.
 33. Lisman T, Leebeek FW, Mosnier LO, Bouma BN, Meijers JC, Janssen HL, 
et al. Thrombin-activatable fibrinolysis inhibitor deficiency in cirrhosis 
is not associated with increased plasma fibrinolysis. Gastroenterology. 
2001;121:131–9.
 34. Williams S, Fatah K, Ivert T, Blomback M. The effect of acetylsalicylic acid 
on fibrin gel lysis by tissue plasminogen activator. Blood Coagul Fibrinoly-
sis. 1995;6:718–25. https ://doi.org/10.1097/00001 721-19951 2000-00004 .
 35. Collet JP, Mishal Z, Lesty C, Mirshahi M, Peynet J, Baumelou A, et al. 
Abnormal fibrin clot architecture in nephrotic patients is related to 
hypofibrinolysis: Influence of plasma biochemical modifications. A pos-
sible mechanism for the high thrombotic tendency? Thromb Haemost. 
1999;82:1482–9. https ://doi.org/10.1055/s-0037-16148 59.
 36. Undas A, Celinska-Löwenhoff M, Löwenhoff T, Szczeklik A. Statins, fenofi-
brate, and quinapril increase clot permeability and enhance fibrinolysis in 
patients with coronary artery disease. J Thromb Haemost. 2006;4:1029–
36. https ://doi.org/10.1111/j.1538-7836.2006.01882 .x.
 37. Formanowicz D, Wanic-Kossowska M, Pawliczak E, Radom M, Formano-
wicz P. Usefulness of serum interleukin-18 in predicting cardiovascular 
mortality in patients with chronic kidney disease-systems and clinical 
approach. Sci Rep. 2015;5:1–13. https ://doi.org/10.1038/srep1 8332.
 38. R Foundation for Statistical Computing. R: a language and environment 
for statistical computing; 2013.
 39. Carter AM, Cymbalista CM, Spector TD, Grant PJ. Heritability of clot forma-
tion, morphology, and lysis: the EuroCLOT study. Arterioscler Thromb Vasc 
Biol. 2007;27:2783–9. https ://doi.org/10.1161/ATVBA HA.107.15322 1.
 40. Chernysh IN, Nagaswami C, Kosolapova S, Peshkova AD, Cuker A, Cines 
DB, et al. The distinctive structure and composition of arterial and venous 
thrombi and pulmonary emboli. Sci Rep. 2020;10:5112. https ://doi.
org/10.1038/s4159 8-020-59526 -x.
 41. Badimon L, Vilahur G. Thrombosis formation on atherosclerotic lesions 
and plaque rupture. J Intern Med. 2014;276:618–32. https ://doi.
org/10.1111/joim.12296 .
 42. Okraska-Bylica A, Wilkosz T, Słowik L, Bazanek M, Konieczyńska M, Undas 
A. Altered fibrin clot properties in patients with premature peripheral 
artery disease. Pol Arch Med Wewn. 2012;122:608–15. https ://doi.
org/10.20452 /pamw.1535.
 43. Barco S, Konstantinides SV. Risk-adapted management of pulmonary 
embolism. Thromb Res. 2017;151:S92–6. https ://doi.org/10.1016/S0049 
-3848(17)30076 -2.
 44. Kearney K, Tomlinson D, Smith K, Ajjan R. Hypofibrinolysis in diabetes: 
a therapeutic target for the reduction of cardiovascular risk. Cardiovasc 
Diabetol. 2017;16:34. https ://doi.org/10.1186/s1293 3-017-0515-9.
 45. Standeven KF, Ariens RAS, Whitaker P, Ashcroft AE, Weisel JW, Grant PJ. The 
effect of dimethylbiguanide on thrombin activity, FXIII activation, fibrin 
polymerization, and fibrin clot formation. Diabetes. 2002;51:189–97. https 
://doi.org/10.2337/diabe tes.51.1.189.
 46. Ajjan RA, Grant PJ. Cardiovascular disease prevention in patients with 
type 2 diabetes: the role of oral anti-diabetic agents. Diabetes Vasc Dis 
Res. 2006;3:147–58. https ://doi.org/10.3132/dvdr.2006.023.
 47. Weisel JW, Litvinov RI. Fibrin formation, structure and properties. Subcell 
Biochem. 2017;82:405–56. https ://doi.org/10.1007/978-3-319-49674 -0.
 48. Lados-Krupa A, Konieczynska M, Chmiel A, Undas A. Increased oxidation 
as an additional mechanism underlying reduced clot permeability and 
impaired fibrinolysis in type 2 diabetes. J Diabetes Res. 2015. https ://doi.
org/10.1155/2015/45618 9.
 49. Bryk A, Konieczynska M, Rostoff P, Broniatowska E, Hohendorff J, Malecki 
M, et al. Plasma protein oxidation as a determinant of impaired fibrinoly-
sis in type 2 diabetes. Thromb Haemost. 2019;119:213–22. https ://doi.
org/10.1055/s-0038-16766 09.
 50. Bhatt DL, Eikelboom JW, Conolly SJ, Steg PG, Anand SS, Verma S, et al. 
Role of combination antiplatelet and anticoagulation therapy in diabetes 
mellitus and cardiovascular disease Insights From the COMPASS Trial. 
Circulation. 2020;141:1841–54. https ://doi.org/10.1161/CIRCU LATIO 
NAHA.120.04644 8.
 51. Ajjan RA, Standeven KF, Khanbhai M, Phoenix F, Gersh KC, Weisel JW, et al. 
Effects of aspirin on clot structure and fibrinolysis using a novel in vitro 
cellular system. Arterioscler Thromb Vasc Biol. 2009;29:712–7. https ://doi.
org/10.1161/ATVBA HA.109.18370 7.
 52. Carter RLR, Talbot K, Hur WS, Meixner SC, van der Gugten JG, Holmes 
D, et al. Rivaroxaban and apixaban induce clotting factor Xa fibrinolytic 
activity. J Thromb Haemost. 2018;16:2276–88. https ://doi.org/10.1111/
jth.14281 .
 53. Schneider JG, Isermann B, Kleber ME, Wang H, Boehm BO, Grammer 
TB, et al. Inverse association of the endogenous thrombin potential 
(ETP) with cardiovascular death: the Ludwigshafen Risk and Cardiovas-
cular Health (LURIC) study. Int J Cardiol. 2014;176:139–44. https ://doi.
org/10.1016/j.ijcar d.2014.07.026.
 54. Van PPCS, Panova-noeva M, Van OR, Hermanns IM, Prochaska JH, Arnold 
N, et al. Thrombin generation in cardiovascular disease and mortality—
results from the Gutenberg Health Study. Haematologica. 2020;105:2327–
34. https ://doi.org/10.3324/haema tol.2019.22165 5.
 55. Tian R, Tian M, Wang L, Qian H, Zhang S, Pang H, et al. Cytokine C-reactive 
protein for predicting cardiovascular and all-cause mortality in type 2 
diabetic patients: a meta-analysis. Cytokine. 2019;117:59–64. https ://doi.
org/10.1016/j.cyto.2019.02.005.
 56. Castoldi E, Rosing J. Thrombin generation tests. Thromb Res. 
2011;127:S21–5. https ://doi.org/10.1016/S0049 -3848(11)70007 -X.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in pub-
lished maps and institutional affiliations.
